Supriya Lifescience Quarterly Results

Pros & Cons

POSITIVES

Overall revenue growth improved, indicating increasing demand for pharmaceutical products in the manufacturing sector.
Cost of goods sold declined as a percentage of revenue, enhancing gross margins significantly.
Strong cash flow generation supports future investments and potential expansion efforts.

NEGATIVES

Net profit margin has shown volatility, raising concerns about consistent profitability.
Rising operational costs have begun to impact the bottom line, suggesting efficiency challenges.
High debt levels could pose risks in periods of economic downturn or rising interest rates.

Field	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
Revenue	140.09	140.07	158.18	160.63	166.10	185.65	184.11	145.07
Expenses	108.34	98.59	102.68	98.08	101.39	119.70	116.52	93.37
Operating Profit	31.75	41.49	55.50	62.54	64.72	65.95	67.58	51.70
Other Income	2.47	3.06	2.19	2.22	2.52	2.10	2.98	2.67
Interest	0.46	0.49	0.60	0.34	0.43	0.51	0.42	0.51
Depreciation	3.98	3.96	3.91	4.66	4.74	4.96	6.08	6.45
Profit Before Tax	29.78	40.10	53.17	59.77	62.06	62.58	64.06	47.41
Tax	5.89	10.31	16.24	15.13	15.92	15.80	13.68	12.62
Net Profit	23.88	29.79	36.93	44.64	46.15	46.78	50.38	34.79
Eps in Rs	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32